Alexander O. Schuth - Jul 17, 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
COFO and Secretary
Signature
/s/ Alexander Schuth
Stock symbol
DNLI
Transactions as of
Jul 17, 2023
Transactions value $
-$534,357
Form type
4
Date filed
7/19/2023, 05:10 PM
Previous filing
May 17, 2023
Next filing
Aug 14, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Options Exercise $52.8K +10K +1.89% $5.28* 539K Jul 17, 2023 See footnote F1, F2
transaction DNLI Common Stock Sale -$296K -10K -1.86% $29.60 529K Jul 17, 2023 See footnote F2, F3, F4
transaction DNLI Common Stock Sale -$291K -9.7K -1.84% $30.01 519K Jul 18, 2023 See footnote F2, F3, F5
holding DNLI Common Stock 132K Jul 17, 2023 Direct F6, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNLI Stock Option (right to buy) Options Exercise $0 -10K -12.67% $0.00 68.9K Jul 17, 2023 Common Stock 10K $5.28 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Exercised shares were issued to the Schuth Family Trust.
F2 The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
F3 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.
F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.33 to $29.94 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.04 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6 Includes 1,030 shares acquired under the ESPP Purchase on May 31, 2023.
F7 Includes 119,156 RSUs.
F8 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter.